Aventis Lovenox Generics Defense Includes Re-Issuance Of Patent
Executive Summary
Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30
You may also be interested in...
Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition